Cho S I, Bradley J W, Carpenter C B, Cosimi A B, Monaco A P
Am J Surg. 1983 Apr;145(4):464-71. doi: 10.1016/0002-9610(83)90041-7.
Three hundred forty-seven recipients of primary cadaver kidney transplants were analyzed in relation to ATG therapy, pretransplant transfusion, HLA-A, -B and -DR antigen matches, and level of PRA to the panel. Prophylactic ATG treatment increased transplant survival significantly when compared with the non-ATG group. The beneficial effect of pretransplant blood transfusions was not apparent when the recipients received prophylactic ATG treatment. No correlation was noted between HLA-A and -B antigen matches and transplant survival. There was no significant difference in the transplant survival between patients with zero DR antigen match kidneys and those with one DR antigen-match kidney. The number of transplants with two DR antigen-match kidneys was too small to be conclusive. The recipients in whom PRA did not develop despite pretransplant blood transfusions seemed to have better transplant survival than those in whom PRA did develop in response to blood transfusions.
对347例初次接受尸体肾移植的受者,就抗胸腺细胞球蛋白(ATG)治疗、移植前输血、HLA - A、- B和 - DR抗原匹配以及群体反应性抗体(PRA)水平与移植组的关系进行了分析。与未接受ATG治疗的组相比,预防性ATG治疗显著提高了移植肾的存活率。当受者接受预防性ATG治疗时,移植前输血的有益效果并不明显。未发现HLA - A和 - B抗原匹配与移植肾存活之间存在相关性。DR抗原无匹配肾的患者与有一个DR抗原匹配肾的患者之间,移植肾存活率无显著差异。有两个DR抗原匹配肾的移植例数太少,无法得出结论。尽管移植前输血但未产生PRA的受者,其移植肾存活率似乎比因输血而产生PRA的受者更好。